Opendata, web and dolomites

TECNEC SIGNED

Preclinical concept validation of tumor endothelial cell metabolism for novel anti-angiogenic therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TECNEC project word cloud

Explore the words cloud of the TECNEC project. It provides you a very rough idea of what is the project "TECNEC" about.

block    vitro    preclinical    silico    transcriptomic    tumors    biomex    predict    treatments    main    fundamentally    validated    rank    screen    nourish    omics    hyperactive    inhibition    fuelling    activate    knockout    followed    nothing    platform    clinical    differ    necs    house    genome    vessel    shrna    tissue    validation    analyze    normalize    angiogenesis    nec    inhibitors    metabolomic    though    sufficient    gems    healthy    metabolism    pioneered    models    genes    rationale    tumor    inhibiting    demonstrated    vivo    lack    anti    tec    biologically    versus    perform    angiogenic    methodology    hypothesize    conditional    bioinformatics    manner    novelty    horizons    construct    metabolic    hyper    promise    computational    tecs    endothelial    deregulated    modeling    therapy    data    cancer    background    cells    isolated    negative    mice    promises    treatment    normal    blood    patients    pioneering    network    dismissed    stimulate    validate    efficacy    driving   

Project "TECNEC" data sheet

The following table provides information about the project.

Coordinator
VIB VZW 

Organization address
address: RIJVISSCHESTRAAT 120
city: ZWIJNAARDE - GENT
postcode: 9052
website: www.vib.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 2˙500˙000 €
 EC max contribution 2˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-ADG
 Funding Scheme ERC-ADG
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2022-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VIB VZW BE (ZWIJNAARDE - GENT) coordinator 2˙500˙000.00

Map

 Project objective

MAIN GOAL: To characterize the metabolic changes, fuelling growth of tumor endothelial cells (TECs) versus normal healthy endothelial cells (NECs), and identify & validate metabolic genes, deregulated in TECs, as targets for anti-angiogenic cancer therapy.

BACKGROUND & RATIONALE: Tumors stimulate blood vessel growth (angiogenesis) to nourish cancer cells, but current anti-angiogenic treatments lack sufficient efficacy. NECs are widely used for anti-angiogenesis development, but TECs, the real target cells, have been dismissed, even though they differ fundamentally from NECs. We pioneered NEC metabolism research and demonstrated that inhibition of specific metabolic pathways can block angiogenesis. Nothing is however known on TEC metabolism. I hypothesize that TECs “hyper-activate” their metabolism in a tissue-specific manner, and that targeting TEC metabolism is a novel concept for inhibiting tumor angiogenesis.

METHODOLOGY: We will perform a transcriptomic and metabolomic analysis of TECs & NECs isolated from cancer patients, use an in-house developed bioinformatics platform (BIOMEX) to analyze the omics data in order to rank deregulated metabolic genes, and construct TEC-tailored genome scale metabolic network models (GEMs) allowing in silico computational modeling to predict metabolic targets that affect TEC but not NEC growth. The in vitro angiogenic activity of top targets will be biologically validated directly or after a negative selection shRNA-based screen, followed by validation in preclinical tumor models in vivo, using conditional knockout mice. All procedures are operational. Deliverables include in vivo validated metabolic targets, driving tumor angiogenesis.

NOVELTY, OVERALL & CLINICAL IMPACT: These pioneering studies on TEC metabolism promise to open up new horizons/opportunities for cancer research. Treatment with inhibitors of the validated targets promises to normalize hyperactive TEC metabolism as a novel anti-angiogenic cancer therapy.

 Publications

year authors and title journal last update
List of publications.
2018 Shawez Khan, Federico Taverna, Katerina Rohlenova, Lucas Treps, Vincent Geldhof, Laura de Rooij, Liliana Sokol, Andreas Pircher, Lena-Christin Conradi, Joanna Kalucka, Luc Schoonjans, Guy Eelen, Mieke Dewerchin, Tobias Karakach, Xuri Li, Jermaine Goveia, Peter Carmeliet
EndoDB: a database of endothelial cell transcriptomics data
published pages: D736-D744, ISSN: 0305-1048, DOI: 10.1093/nar/gky997
Nucleic Acids Research 47/D1 2019-09-02

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TECNEC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TECNEC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ENTRAPMENT (2019)

Septins: from bacterial entrapment to cellular immunity

Read More  

EASY-IPS (2019)

a rapid and efficient method for generation of iPSC

Read More  

ORGANITRA (2019)

Transport of phosphorylated compounds across lipid bilayers by supramolecular receptors

Read More